Research programme: anti-infective monoclonal antibodies - AIMM Therapeutics

Drug Profile

Research programme: anti-infective monoclonal antibodies - AIMM Therapeutics

Alternative Names: Anti Staph A mAb rF1; Bispecific influenza virus antibody; Clostridium difficile antibody; Cytomegalovirus antibody; Hepatitis C virus antibody; Parechovirus antibody; rF1

Latest Information Update: 25 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AIMM Therapeutics
  • Developer AIMM Therapeutics; Genentech
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Picornavirus infections

Highest Development Phases

  • Preclinical Methicillin-resistant Staphylococcus aureus infections
  • No development reported Cytomegalovirus infections; Hepatitis C; Picornavirus infections
  • Discontinued Clostridium-difficile-infections

Most Recent Events

  • 25 Jan 2018 Preclinical development for Methicillin-resistant Staphylococcus aureus infections is ongoing (AIMM Therapeutics pipeline, January 2018)
  • 25 Jan 2018 Discontinued for Clostridium difficile infections in Netherlands (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in Netherlands (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top